Arkolith/Insider Trading/SGMT/Form 4

Kemble George

Executive Chairman, DirectorSagimet Biosciences Inc. (SGMT) · full profile →Form 4 · filed Nov 21, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$290K
Net Open-Market Flow
-$290K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 20, 2025Sell(S)38K$7.69$290K81K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-115071) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML